Korean biotech and pharmaceutical companies will gather at BIO-Europe 2026 in Cologne, Germany, from the 9th to the 11th to pursue licensing, joint-development and investment partnerships with global drugmakers. Alteogen will discuss commercialization of ALTS-OP01, a macular-degeneration candidate designed to modulate four targets while extending treatment duration, and seek partners for its Hybrozyme platform, which converts antibody-drug conjugates into subcutaneous injections. D&D Pharmatech will introduce DD18, an obesity candidate focused on limiting muscle loss during weight reduction, while continuing licensing discussions for zavopegdutide (DD01), a MASH candidate that showed potential in a completed Phase 2 trial to reduce liver fat and improve fibrosis. Ligachem Biosciences will present clinical- and preclinical-stage ADC programs and its ConjuAll platform. ABL Bio will seek partners for its Grabody-B blood-brain-barrier platform and Grabody-T bispecific antibody immuno-oncology platform, led by Phase 2 candidate givastomig. G2Gbio will present the month-long dementia candidate GB-5001 and high-concentration subcutaneous antibody technology. Jeil Pharmaceutical is also scheduled to showcase JP-2266, JP9441 and Duglow, covering diabetes, oncology and metabolic treatment programs.